- ►ypertasi.gr [PDF] JG Robinson, N Maheshwari - The American journal of cardiology, 2005 - Elsevier A “polypill” for the primary prevention of cardiovascular disease has been
proposed. We estimated the projected benefit of a secondary prevention
“poly-portfolio” strategy, including pharmacologic and lifestyle ... Cited by 28 - Related articles - All 13 versions
S Takai, K Kirimura, D Jin, M Muramatsu, K … - Hypertension Research, 2005 - nature.com Although the lipophilicities of the various angiotensin II receptor blockers
(ARBs) are very different, the relationship between lipophilicity and the
protective effect against vascular remodeling is unclear. In this study, we ... Cited by 24 - Related articles - BL Direct - All 4 versions
S Schneeweiss - Clinical Pharmacology & Therapeutics, 2007 - nature.com Physicians and insurers need to weigh the effectiveness of new drugs against
existing therapeutics in routine care to make decisions about treatment and
formularies. Because Food and Drug Administration (FDA) approval of most ... Cited by 27 - Related articles - All 5 versions
CS Carter, G Onder, SB Kritchevsky, M Pahor - Journals of Gerontology Series A: Biological and …, 2005 - Geron Soc America The disablement process is often accompanied by sarcopenia or muscle loss, which
is associated with virtually all identified disability risk factors. Clinically,
the association between body composition and physical performance has been ... Cited by 19 - Related articles - BL Direct - All 3 versions
G Salanti, J Higgins, AE Ades, J Ioannidis - Statistical methods in medical research, 2008 - smm.sagepub.com Randomized trials may be designed and interpreted as single experiments or they
may be seen in the context of other similar or relevant evidence. The amount and
complexity of available randomized evidence vary for different topics. ... Cited by 20 - Related articles - All 3 versions
SO Kasper, N Basso, ML Kurnjek, N Paglia, CM … - Am J Nephrol, 2005 - content.karger.com Background/Aims: Long-term treatment with angiotensin-converting enzyme (ACE)
inhibitors or angiotensin (Ang) II type I (AT 1 ) receptor blockers can improve
kidney function and attenuate the progressive decline in kidney function ... Cited by 19 - Related articles - BL Direct - All 5 versions
EB Friedrich, KK Teo, M Böhm - Clinical Research in Cardiology, 2006 - Springer The mechanisms of action behind these beneficial cardiovascular effects of ACE
inhibitors have been studied in numerous experimental systems both in vitro and
in vivo. ACE inhibitors decrease the for- mation of the potent ... Cited by 14 - Related articles - BL Direct - All 3 versions
S Rinfret, M Abrahamowicz, J Tu, K Humphries … - American heart journal, 2007 - Elsevier Among 31 576 patients, 67% were prescribed with metoprolol, 24% with atenolol,
and 9% with acebutolol. Clinical characteristics and proportion of days covered
with a β-blocker prescription were similar across groups. Although ... Cited by 13 - Related articles - All 23 versions
CJ Boos - Medical science monitor: international medical journal …, 2004 - ncbi.nlm.nih.gov BACKGROUND: Treatment with angiotensin converting enzyme (ACE) inhibitors
reduces mortality and morbidity among patients with heart failure,
left-ventricular dysfunction after myocardial infarction and with ... Cited by 12 - Related articles - All 4 versions
- ►adisonline.com [PDF] C Fenton, LJ Scott - Drugs, 2005 - ingentaconnect.com 0012-6667/05/0004-0537/$39.95/0 2005 Adis Data Information BV. All rights
reserved. ... A Review of its Use In the Management of Chronic Heart Failure ... Various sections of the manuscript reviewed by: G. Cioffi, Department ... Cited by 11 - Related articles - All 8 versions
